Patients for Affordable Drugs Action launches massive election campaign
The drug pricing advocacy group Patients for Affordable Drugs Action announced Tuesday a multi-million dollar 15-state campaign ahead of the November election. The campaign will focus on TV, radio, and digital ads urging voters to back candidates who support reforming the U.S. drug pricing system.
The group, which made waves last election cycle when it unsuccessfully challenged incumbent and health care leader Rep. Anna Eshoo, has not yet publicly endorsed candidates this election cycle. A spokesperson told STAT that endorsements are coming and some of the ads in this new campaign will mention candidates, but that the initial ads won’t.
“Tuesday’s announcement is more of a counterweight to Big Pharma. We’re encouraging people to cast their votes for candidates who will work to reform our rigged system and pass legislation to lower drug prices — whoever they are,” the spokesperson said.
The first ad, which features a 27-year old struggling to pay for her ulcerative colitis drugs, will run in Virginia, Montana, Minnesota, Iowa, and Georgia. The ads direct viewers to a new website, fightpharma.org, where patients can sign a petition and tweet their support for lowering drug prices.
The group, which made waves last election cycle when it unsuccessfully challenged incumbent and health care leader Rep. Anna Eshoo, has not yet publicly endorsed candidates this election cycle. A spokesperson told STAT that endorsements are coming and some of the ads in this new campaign will mention candidates, but that the initial ads won’t.
“Tuesday’s announcement is more of a counterweight to Big Pharma. We’re encouraging people to cast their votes for candidates who will work to reform our rigged system and pass legislation to lower drug prices — whoever they are,” the spokesperson said.
The first ad, which features a 27-year old struggling to pay for her ulcerative colitis drugs, will run in Virginia, Montana, Minnesota, Iowa, and Georgia. The ads direct viewers to a new website, fightpharma.org, where patients can sign a petition and tweet their support for lowering drug prices.
STAT stories you may have missed
From shipping containers to security concerns, a Covid-19 vaccine supply chain is taking shape.
Inside Gilead’s $21 billion purchase of Immunomedics: Lamb chops, steak, and a chance for transformation.
In Kansas, two doctors are squaring off for a Senate seat. But their approaches to health policy and the Covid-19 pandemic couldn’t be more different.
Operation Warp Speed promised to do the impossible. How far has it come?
Pharma drew a line in the sand over Covid-19 vaccine readiness — because someone had to, STAT's Ed Silverman writes.
Watch: STAT’s Helen Branswell answers your questions about Covid-19, reinfection, and vaccine efficacy.
A United Kingdom-based Phase 2/3 study of AstraZeneca's Covid-19 vaccine candidate has resumed — but not the U.S. trial.
As health tech flourished, Teladoc and Livongo saw an opportunity to ‘accelerate,’ executives say.
The public’s trust in the CDC and health officials like Fauci is rapidly dropping, particularly among Republicans, according to a new poll.
Inside Gilead’s $21 billion purchase of Immunomedics: Lamb chops, steak, and a chance for transformation.
In Kansas, two doctors are squaring off for a Senate seat. But their approaches to health policy and the Covid-19 pandemic couldn’t be more different.
Operation Warp Speed promised to do the impossible. How far has it come?
Pharma drew a line in the sand over Covid-19 vaccine readiness — because someone had to, STAT's Ed Silverman writes.
Watch: STAT’s Helen Branswell answers your questions about Covid-19, reinfection, and vaccine efficacy.
A United Kingdom-based Phase 2/3 study of AstraZeneca's Covid-19 vaccine candidate has resumed — but not the U.S. trial.
As health tech flourished, Teladoc and Livongo saw an opportunity to ‘accelerate,’ executives say.
The public’s trust in the CDC and health officials like Fauci is rapidly dropping, particularly among Republicans, according to a new poll.
.png)
No hay comentarios:
Publicar un comentario